Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling

AIM: To investigate the molecular mechanisms underlying the reversal effect of emodin on platinum resistance in hepatocellular carcinoma. METHODS: After the addition of 10 μmol/L emodin to HepG2/oxaliplatin (OXA) cells, the inhibition rate (IR), 50% inhibitory concentration (IC 50 ) and reversal index (IC 50 in experimental group/IC 50 in control group) were calculated. For HepG2, HepG2/OXA, HepG2/OXA/T, each cell line was divided into a control group, OXA group, OXA + fibroblast growth factor 7 (FGF7) group and OXA + emodin group, and the final concentrations of FGF7, emodin and OXA in each group were 5 ng/mL, 10 μg/mL and 10 μmol/L, respectively. Single-cell gel electrophoresis was conducted to detect DNA damage, and the fibroblast growth factor receptor 2 (FGFR2), phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK1/2) and excision repair cross-complementing gene 1 (ERCC1) protein expression levels in each group were examined by Western blotting. RESULTS: Compared with the IC50 of 120.78 μmol/L in HepG2/OXA cells, the IC 50 decreased to 39.65 μmol/L after treatment with 10 μmol/L emodin; thus, the reversal index was 3.05. Compared with the control group, the tail length and Olive tail length in the OXA group, OXA + FGF7 group and OXA + emodin group were significantly increased, and the differences were statistically significant (P < 0.01). The tail length and Olive tail length were lower in the OXA + FGF7 group than in the OXA group, and this difference was also statistically significant. Compared with the OXA + FGF7 group, the tail extent, the Olive tail moment and the percentage of tail DNA were significantly increased in the OXA + emodin group, and these differences were statistically significant (P < 0.01). In comparison with its parental cell line HepG2, the HepG2/OXA cells demonstrated significantly increased FGFR2, p-ERK1/2 and ERCC1 expression levels, whereas the expression of all three molecules was significantly inhibited in HepG2/ OXA/T cells, in which FGFR2 was silenced by FGFR2 shRNA. In the examined HepG2 cells, the FGFR2, p-ERK1/2 and ERCC1 expression levels demonstrated increasing trends in the OXA group and OXA + FGF7 group. Compared with the OXA group and OXA + FGF7 group, the FGFR2, p-ERK1/2, and ERCC1 expression levels were significantly lower in the OXA + emodin group, and these differences were statistically significant. In the HepG2/OXA/T cell line that was transfected with FGFR2 shRNA, the FGFR2, p-ERK1/2 and ERCC1 expression levels were significantly inhibited, but there were no significant differences in these expression levels among the OXA, OXA + FGF7 and OXA + emodin groups. CONCLUSION: Emodin markedly reversed OXA resistance by enhancing OXA DNA damage in HepG2/OXA cells, and the molecular mechanism was related to the inhibitory effect on ERCC1 expression being mediated by the FGFR2/ERK1/2 signaling pathway.

Basic Fibroblast Growth Factor and Fibroblast Growth Factor Receptor-1 in Human Meningiomas

The expression of basic fibroblast growth factor (bFGF) and fibroblast growth factor receptor-1 (FGFR-1) in human meningiomas and the relationships between their expression and the tumors' histological features and angiogenesis were investigated by means of immunohistochemical technique. The expression of bFGF and FGFR-1 was detected by antibody of bFGF or FGFR-1. The tumors' angiogenesis was evaluated by microvascular density (MVD) and, which was observed by use of CD34-antibody immunohistochemically. The results showed that there were varied degrees of the expression of bFGF and FGFR-1 proteins in meningiomas. The expression was correlated with the tumors' histological characters and angiogenesis. It was concluded that bFGF and FGFR-1 might play important roles in meningiomas' angiogenesis and proliferation. The expression positive rate of bFGF and FGFR-1 may provide an indication of evaluating the histological and malignant degree of the tumor.

Role of fibroblast growth factor receptor 1 in the bone development and skeletal diseases

Accumulating data suggest that FGFs/FGFR1 plays essential roles in the bone development and human skeletal diseases.Conditional inactivation of fgfr1 caused different phenotypes displaying in different cells or specific organs and revealed some novel functions of FGFR1 in bone development.Fgfr1 mutation mainly induced 2 types of human skeletal diseases,craniosynostosis syndrome and dysplasias. Similar mutation of fgfr1 in mouse model just mimicked the phenotype that happened in human.These fa- cilitate the investigation on the underlying mechanism of the diseases.Here we mainly focused on the ad- vance of FGFR1 function in the bone development and its mutation caused skeletal diseases.

RNA interference affects tumorigenicity and expression of insulin-like growth factor-1,insulin-like growth factor-1 receptor,and basic fibroblast growth factor-2 in rat C6 glioma cells

BACKGROUND： Human gliomas are more likely to express basic fibroblast growth factor-2 （FGF-2） insulin-like growth factor-1（IGF-1）, and IGF-1 receptor （IGF-1R） than normal brain tissue. These factors activate signal transduction systems of Ras/MAPK and PI3K/Akl, which promote glioma growth. OBJECTIVE： To utilize RNA interference （RNAi） technique to down-regulate FGF-2, IGF-1, and IGF-1R gene expression, and to investigate the effects of these genes on rat C6 glioma cells, as well as the feasibility of RNAi for treating glioma. DESIGN, TIME AND SETTING： This neurooncological, randomized, controlled, in vivo and in vitro experiment, which used RNAi methodology, was performed at the Laboratory of Molecular Biology, Institute of Biochemistry, Chinese Academy of Sciences between August 2005 and February 2008. MATERIALS： Rat C6 cell lines were purchased from Shanghai Institute of Cellular Biology Affiliated to Chinese Academy of Sciences. Small interfering RNA （siRNA） was synthesized by Shanghai GenePharma. Anti-IGF-1, anti-IGF-1R, anti-FGF-2, anti-mouse and anti-rabbit IgG G1-HRP antibodies were provided by Santa Cruz Biotechnology, USA. Four to six week-old BALB/c nude mice were purchased from the Laboratory Animal Center, Chinese Academy of Sciences. METHODS： C6 glioma cells were transfected with siRNA, which was chemically synthesized in vitro to correspond to endogenous FGF-2, IGF-1, and IGF-1R genes. The inhibition ratio of targeting mRNA expression was detected by semiquantitative RT-PCR, and protein expression was determined by Western blot analysis. C6 glioma cell proliferation was observed using a growth curve C6 glioma cell apoptosis rate and cell cycle were detected by flow cytometry. C6 glioma cell growth regression was observed by transwell migration assay. In addition, nude mouse subcutaneous tumor models were used in this study. For studying the anti-tumor effects of IGF-1 and IGF-1R siRNA, two blank control groups, with six mice each, were set up： A （2.5 μg siRNA was injected one week after C6 cells were inoculated, Le., when tumor volume reached 8 mm × 8 mm） and B （siRNA was injected at the same time with C6 cells were inoculated. To study the effects of FGF-2 siRNA, the groups consisted of a blank control group, negative control group, 2.6 μg siRNA group, 4 μg siRNA group, and 5.3 μg siRNA group, with six mice each. MAIN OUTCOME MEASURES： mRNA and protein inhibition ratio of FGF-2, IGF-1, and IGF-1 R; C6 glioma cell proliferation, apoptosis, and cycle growth arrest; C6 glioma cell growth regression and subcutaneous tumorigenicity rates. RESULTS： All siRNA constructs proved to be effective. After 48 hours, transfection of 200 nmol/L siRNA resulted in a FGF-2 or IGF-1R gene inhibition ratio 〉 80% and an IGF-1 gene inhibition ratio of approximately 70%. Protein expression levels for FGF-2, IGF-1, and IGF-1R decreased in a dose-dependent manner following siRNA transfection, with an inhibition rate 〉 85%, 60%, and 50%, respectively. C6 glioma cell proliferation and apoptosis rates increased in proportion to siRNA. The apoptosis rate of C6 glioma cells induced by FGF-2, IGF-1, and IGF-1R siRNA was 39.96%, 15.07% and 22.47%, respectively （P 〈 0.01）. Transfection of 200 nmol/L IGF or IGF-1R siRNA for 48 hours suppressed C6 glioma cell migration. At 30 days after intratumoral injection of 2.6, 4, and 5.3 tJg FGF-2 siRNA, tumor growth regression rate of FGF-2 siRNA was 56%, 67%, and 86%, respectively. The tumor growth regression rate was 71.88% and 45.71%, respectively, when IGF-1 or IGF-1R siRNA was intratumorally injected 1 week after C6 glioma cell transplantation. When IGF-1 or IGF-1 R siRNA was intratumorally injected during C6 glioma cell transplantation, the tumor growth regression rate was 78.13% and 74.29%, respectively. CONCLUSION： siRNA transfection downregulated gene expression of FGF-2, IGF-1, and IGF-1R In addition, siRNA treatment markedly suppressed glioma cell proliferation, growth, and migration, and concomitantly reduced subcutaneous tumorigenicity.

EXPRESSION AND SIGNIFICANCE OF BASIC FIBROBLAST GWOWTH FACTOR AND FIBROBLAST GROWTH FACTOR RECEPTOR-1 IN OVARIAN EPITHELIAL NEOPLASM

Objective To study the relevance of expression of basic fibroblast growth factor (bFGF), fibroblast growth factor receptor 1 (FGFR 1) and carcinogenesis and progression of ovarian epithelial neoplasm. Methods Ten cases of normal ovarian tissues and 75 cases of ovarian epithelial neoplasm tissues were detected by immunohistochemical methods: S P for bFGF, FGFR 1,double immunohistochemistry Lab SA for Ki 67 antigen and bFGF. Results The expression level of bFGF, FGFR 1in ovarian epithelium and ovarian epithelial neoplasm showed a step wise increase in the following order:normal <benign <borderline <malignant; The expression level and intensity of bFGF and FGFR 1 were increased with the decrease of differentiation degree and increase of clinical stage in ovarian carcinoma; There was no statistical difference between the expression of bFGF, FGFR 1 in serous cystadenocarcinoma and that of mucinous cystadenocarcinoma; The expression of bFGF was correlated with that of FGFR 1 in neoplastic tissues; There were positive expression rates of bFGF and Ki 67 antigen in ovarian epithelial neoplasm. Conclusion As an important proliferative factor, bFGF plays an important role in carcinogenisis and progression of ovarian epithelial neoplasm.

Are there fibroblast growth factor receptor 1 mutations in a Chinese Kallmann syndrome family?

The present study examined 58 members of a Kallmann syndrome family and investigated whether there are fibroblast growth factor receptor 1 （FGFR1） gene mutations in this family. Genomic DNA from the proband and family members was subjected to PCR to amplify 18 exons of FGFR1, and the amplified products were sequenced to identify potential mutations. MRI of the olfactory bulb region was performed on suspected subjects. The patient and his father were diagnosed with Kallmann syndrome. A polymorphic site was found at 39542, with the proband and his parents being heterozygous （guanine ＋ cytosine）. However, healthy controls and the other members of this family were homozygous for guanine at this position.

Expression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 protein in the hippocampus in rats exhibiting chronic stress-induced depression

There is evidence that the expression of members of the fibroblast growth factor （FGF） protein family is altered in post-mortem brains of humans suffering from major depressive disorder. The present study examined whether the expression of fibroblast growth factor-2 （FGF2） and fibroblast growth factor receptor-1 （FGFR1） protein is altered following chronic stress in an animal model. Rats were exposed to 35 days of chronic unpredictable mild stress, and then tested using open-field and sucrose consumption tests. Compared with the control group, rats in the chronic stress group exhibited obvious depressive-like behaviors, including anhedonia, anxiety and decreased mobility. The results of western blot analysis and immunohistochemical analysis revealed a downregulation of the expression of FGF2 and FGFR1 in the hippocampus of rats, particularly in the CA1, CA3 and dentate gyrus. This decreased expression is in accord with the results of post-mortem studies in humans with major depressive disorder. These findings suggest that FGF2 and FGFR1 proteins participate in the pathophysiology of depressive-like behavior, and may play an important role in the mechanism of chronic stress-induced depression.

Basic fibroblast growth factor gene transfection in repair of internal carotid artery aneurysm wall

Surgery or interventional therapy has some risks in the treatment of cerebral aneurysm. We established an internal carotid artery aneurysm model by dripping elastase in the crotch of the right internal and external carotid arteries of New Zealand rabbits. Following model induction, lentivirus carrying basic fibroblast growth factor was injected through the ear vein. We found that the longer the action time of the lentivirus, the smaller the aneurysm volume. Moreover, platelet-derived growth factor expression in the aneurysm increased, but smooth muscle 22 alpha and hypertension-related gene 1 mRNA expression decreased. At 1,2, 3, and 4 weeks following model establishment, following 1 week of injection of lentivirus carrying basic fibroblast growth factor, the later the intervention time, the more severe the blood vessel damage, and the bigger the aneurysm volume, the lower the smooth muscle 22 aJpha and hypertension-related gene ~ mRNA expression. Simultaneously, platelet-derived growth factor expression decreased. These data suggest that recombinant lentivirus carrying basic fibroblast growth factor can repair damaged cells in the aneurysmal wall and inhibit aneurysm dynamic growth, and that the effect is dependent on therapeutic duration.

Exogenous acid fibroblast growth factor inhibits ischemia-reperfusion-induced damage in intestinal epithelium via regulating P53 and P21WAF-1 expression

AIM: To detect the effect of acid fibroblast growth factor (aFGF) on P53 and P21WAF-1 expression in rat intestine after ischemia-reperfusion (I-R) injury in order to explore the protective mechanisms of aFGF.METHODS: Male rats were randomly divided into four groups, namely intestinal ischemia-reperfusion group (R),aFGF treatment group (A), intestinal ischemia group (I),and sham-operated control group (C). In group I, the animals were killed after 45 min of superior mesenteric artery (SMA) occlusion. In groups R and A, the rats sustained for 45 min of SMA occlusion and were treated with normal saline (0.15 mL) and aFGF (20 μg/kg, 0.15 mL),then sustained at various times for up to 48 h after reperfusion. In group C, SMA was separated, but without occlusion. Apoptosis in intestinal villi was determined with terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling technique (TUNEL).Intestinal tissue samples were taken not only for RTPCR to detect P53 and P21WAF-1 gene expression, but also for immunohistochemical analysis to detect P53 and P21WAF-1 protein expression and distribution.RESULTS: In histopathological study, ameliorated intestinal structures were observed at 2, 6, and 12 h after reperfusion in A group compared to R group. The apoptotic rates were (41.17±3.49)%, (42.83±5.23)%,and (53.33±6.92)% at 2, 6, and 12 h after reperfusion,respectively in A group, which were apparently lower than those in R group at their matched time points(50.67±6.95)%, (54.17±7.86)%, and (64.33±6.47)%,respectively, (P＜0.05)). The protein contents of P53and P21WAF-1 were both significantly decreased in A group compared to R group (P＜0.05) at 2-12 h after reperfusion, while the mRNA levels of P53 and P21WAF-1in A group were obviously lower than those in R group at6-12 h after reperfusion (P＜0.05).CONCLUSION: P53 and P21WAF-1 protein accumulations are associated with intestinal barrier injury induced by I-R insult, while intravenous aFGF can alleviate apoptosis of rat intestinal cells by inhibiting P53 and P21WAF-1protein expression.

MicroRNA-133b调节FGFR1-ERK1/2-SOX2信号通路对裸鼠肺癌NCI-H1975细胞移植瘤生长的影响

目的探讨microRNA-133b(miR-133b)对裸鼠肺癌NCI-H1975细胞移植瘤生长的抑制作用以及对成纤维细胞生长因子受体1-细胞外信号调节激酶1/2-性别决定区Y-box蛋白2信号通路(FGFR1-ERK1/2-SOX2)的影响。方法q RT-PCR检测人肺成纤维细胞、肺癌细胞株miR-133b表达。miR-133b过表达NCIH1975细胞。将NCI-H1975细胞分为对照组、mimic NC组、miR-133b mimic组、miR-133b mimic+pcDNA3.1组、miR-133b mimic+pcDNA3.1 FGFR1组。CCK-8法检测NCI-H1975细胞增殖抑制率,Transwell实验观察NCI-H1975细胞侵袭、迁移情况。复制裸鼠移植瘤模型并分组,将裸鼠分为对照组、mimic NC组、miR-133b mimic组、miR-133b mimic+AZD4547组,观察各组裸鼠肿瘤体积与重量,HE染色观察各组裸鼠肿瘤组织变化,TUNEL检测肿瘤组织细胞凋亡情况,免疫组织化学法观察裸鼠肿瘤组织Ki-67、Cyclin D1、VEGF-A的表达,Western blotting检测各组肿瘤组织FGFR1、p-ERK1/2/ERK1/2、SOX2蛋白相对表达量。结果与人肺成纤维细胞HLF-α比较,肺癌细胞株NCI-H1975、A427、NGE-1、A549中miR-133b mRNA相对表达量降低(P<0.05),其中以NCI-H1975细胞中miR-133b mRNA相对表达量最低。miR-133b mimic组miR-133b mRNA相对表达量较对照组和mimic NC组升高(P<0.05)。miR-133b可通过负调控FGFR1抑制肺癌NCIH1975细胞增殖和迁移。miR-133b mimic组移植瘤重量较对照组降低、体积缩小,miR-133b mimic+AZD4547组移植瘤重量较miR-133b mimic组降低、体积缩小(P<0.05)。miR-133b mimic组空泡样变性程度较对照组、mimic NC组减轻(P<0.05),miR-133b mimic+AZD4547组空泡样变性程度较miR-133b mimic组减轻(P<0.05)。miR-133b mimic组肿瘤组织细胞凋亡率较对照组升高(P<0.05),miR-133b mimic+AZD4547组肿瘤组织细胞凋亡率较miR-133b mimic组升高(P<0.05)。miR-133b mimic组VEGF-A、Cyclin D、Ki-67阳性细胞比例较对照组降低(P<0.05),miR-133b mimic+AZD4547组VEGF-A、Cyclin D、Ki-67阳性细胞比例较miR-133b mimic组降低(P<0.05)。miR-133b mimic组FGFR1、p-ERK1/2/ERK1/2、SOX2蛋白相对表达量较对照组降低(P<0.05),miR-133b mimic+AZD4547组FGFR1、p-ERK1/2/ERK1/2、SOX2蛋白相对表达量较miR-133b mimic组降低(P<0.05)。结论miR-133b过表达可能通过抑制FGFR1-ERK1/2-SOX2轴,抑制裸鼠肺癌NCI-H1975细胞移植瘤生长。

LPS通过促进FGFR1磷酸化诱导肺上皮细胞炎症反应及凋亡

目的 探讨脂多糖(LPS)通过促进成纤维细胞生长因子受体1(FGFR1)磷酸化的方式诱导肺上皮细胞炎症反应及凋亡。方法 培养肺上皮Beas-2B细胞并进行以下分组处理,以不含药物的培养基处理作为对照组,用5 mg/L LPS刺激作为LPS组,另加入不同浓度FGFR1选择性抑制剂AZD4547(2.5、5.0、10.0μmol/L)作为AZD4547组。采用CCK8法检测各组细胞的增殖活力,Tunel法检测细胞凋亡率,ELISA法检测细胞培养基中TNF-α、IL-1β、IL-6的含量,Western blot检测各组细胞总蛋白中磷酸化成纤维细胞生长因子受体1(p-FGFR1)、B淋巴细胞瘤-2基因(Bcl-2)蛋白、Bcl-2相关X蛋白(Bax)、切割型半胱氨酸天冬氨酸蛋白水解酶-3(cleaved caspase-3)以及核蛋白中p65核因子-κB(NF-κB)的表达水平。结果 LPS组Beas-2B细胞的增殖活力及Bcl-2水平均显著低于对照组(t分别为11.421、17.784,P<0.05),而Beas-2B细胞的细胞凋亡率、p-FGFR1、Bax、cleaved caspase-3、p65 NF-κB水平及培养基中TNF-α、IL-1β、IL-6含量均高于对照组(t分别为9.126、11.329、12.684、13.147、15.027、11.621、8.925、9.726,P<0.05);2.5、5.0、10.0μmol/L浓度AZD4547组Beas-2B细胞的增殖活力及Bcl-2水平均显著高于LPS组(F分别为45.012、72.286,P<0.05),而细胞凋亡率、p-FGFR1、Bax、cleaved caspase-3、 p65 NF-κB水平及培养基中TNF-α、IL-1β、IL-6含量均显著低于LPS组(F分别为43.527, 94.166, 113.028, 102.515, 41.091, 51.301, 30.280,P<0.05),且AZD4547浓度越高,上述变化趋势越显著。结论 LPS诱导肺上皮细胞炎症反应及凋亡激活的作用可能与促进FGFR1磷酸化有关。

肝细胞癌患者血清FGFR1和VEGFA水平与临床病理特征及预后的相关性分析

目的:探讨成纤维细胞生长因子受体-1(FGFR1)和血管内皮生长因子A(VEGFA)在肝细胞癌(HCC)患者血清中的表达,以及与临床病理特征和预后的相关性。方法:选取2018年1月至2019年12月住院治疗的168例HCC患者作为研究对象(HCC组),另选取168例同期门诊健康体检者作为对照组。检测两组受试者血清FGFR1、VEGFA水平;收集HCC患者临床病理特征及随访资料,分析血清FGFR1、VEGFA与临床病理特征的关系;受试者工作特征(ROC)曲线分析血清FGFR1、VEGFA水平对HCC的预测价值;Kaplan-Meier法分析HCC患者血清FGFR1、VEGFA水平与预后的关系;多因素Logistic回归分析HCC患者预后的影响因素。结果:HCC组患者血清FGFR1、VEGFA水平显著高于对照组(P<0.05)。血清FGFR1、VEGFA二者联合预测HCC的AUC为0.774,敏感性为59.52%,特异性为83.33%,优于FGFR1、VEGFA各自单独检测(P<0.05)。HCC组患者血清FGFR1、VEGFA表达水平均与TNM分期、淋巴结转移、分化程度显著相关(P<0.05)。血清FGFR1、VEGFA高表达组HCC患者3年累积生存率低于FGFR1低表达组(P<0.05);血清FGFR1、VEGFA、TNM分期、淋巴结转移、分化程度为HCC患者预后的影响因素(P<0.05)。结论:HCC患者血清FGFR1、VEGFA水平与TNM分期、淋巴结转移、分化程度等临床病理特征及预后有密切联系,检测其表达水平对评估患者预后生存情况具有重要价值。

不同FGFR1突变与先天性低促性腺激素性性腺功能减退症的相关性

目的通过对成纤维细胞生长因子受体1(FGFR1)基因突变的先天性低促性腺激素性性腺功能减退症(CHH)患者多个基因进行筛查,寻找是否同时存在其他基因突变,共同导致疾病发生。方法对15例FGFR1突变CHH患者的突变来源进行验证。对其他CHH相关基因进行筛查。通过生信分析,评价这些突变基因的致病性。结果1)9例患者FGFR1突变来源于生殖表型正常的父/母(遗传突变组)。2)遗传突变组中有6例患者存在其他致病性突变,分别是PROKR2(W178S)、FGF8(T121N)、HS6ST1(P242L)、SEMA3A(R734W)、LZTR1(Q10Rfs15)和FGFR1复合杂合突变。这些突变和FGFR1突变可能一起协同作用导致CHH发生。3)6例FGFR1自发突变(自发突变组)患者中,未发现存在其他CHH相关基因致病性突变。结论来自生殖表型正常父/母的FGFR1突变,存在另一个CHH相关基因突变协同打击才导致CHH。本研究扩展了对双基因突变导致CHH的发病机制认识。

miR-296靶向FGFR1对卵巢癌细胞生长、迁移及侵袭的影响

目的探讨miR-296靶向成纤维细胞生长因子受体1(FGFR1)对卵巢癌细胞生长、迁移及侵袭的影响。方法体外培养人SK-OV-3细胞,并将细胞分为对照组、miR-296 NC组、miR-296 mimics组、miR-296 mimics+FGFR1 NC组、miR-296 mimics+FGFR1组。实时荧光定量PCR(qRT-PCR)检测细胞中miR-296、FGFR1 mRNA水平;细胞计数试剂盒8(CCK-8)检测细胞活力;Transwell法检测细胞迁移和侵袭能力;蛋白免疫印迹(WB)法检测增殖、迁移和侵袭蛋白的表达;双荧光素酶报告实验分析miR-296与FGFR1的靶向关系。结果与对照组比较,miR-296 mimics组miR-296表达显著升高,FGFR1 mRNA表达显著降低(P<0.05);与miR-296 mimics组比较,miR-296 mimics+FGFR1组miR-296表达差异无统计学意义(P>0.05),FGFR1 mRNA表达显著升高(P<0.05)。与对照组比较,miR-296 mimics组细胞活力、迁移和侵袭细胞数目、蛋白FGFR1、增殖蛋白β-catenin、CyclinD1、迁移蛋白MMP-2、侵袭蛋白N-cadherin表达显著降低,E-cadherin蛋白表达显著升高(P<0.05);与miR-296 mimics组比较,miR-296 mimics+FGFR1组细胞活力、迁移和侵袭细胞数目、蛋白FGFR1、β-catenin、CyclinD1、MMP-2、N-cadherin表达显著升高,E-cadherin蛋白表达显著降低(P<0.05);双荧光素酶报告实验表明miR-296和FGFR1存在靶向关系。结论miR-296可能通过靶向FGFR1抑制SK-OV-3细胞EMT途径,抑制细胞生长、迁移和侵袭。

靶向成纤维细胞生长因子受体1信号改善类风湿关节炎的骨破坏

背景:尽管科研人员已注意到成纤维细胞生长因子受体1在类风湿关节炎骨破坏中展现出巨大潜力,但尚未有学者对成纤维细胞生长因子受体1在类风湿关节炎骨破坏中的研究进展作全面综述。目的:通过查阅国内外相关文献,综合分析成纤维细胞生长因子受体1在类风湿关节炎骨破坏中的机制。方法:以“成纤维细胞生长因子受体1,类风湿关节炎,骨破坏,骨细胞,成骨细胞,破骨细胞,软骨细胞,巨噬细胞,滑膜成纤维细胞,T细胞,血管内皮细胞”为检索词检索中国知网数据库,以“fibroblast growth factor receptor 1,rheumatoid arthritis,bone destruction,osteocytes,osteoblasts,osteoclasts,chondrocytes,macrophages,synovial fibroblasts,T cells,endothelial cells”为检索词检索PubMed数据库,检索时间范围重点为1992年4月至2024年1月。通过阅读文献题目、摘要及全文,根据纳入与排除标准进行筛选,最后纳入82篇文献进行综述。结果与结论:成纤维细胞生长因子受体1广泛表达于骨组织相关细胞,包括骨细胞、成骨细胞、破骨细胞等,可以通过调控这些细胞的功能来影响骨重塑过程和维持骨稳态,促进类风湿关节炎骨破坏的发生和发展。成纤维细胞生长因子受体1还可以在滑膜成纤维细胞和巨噬细胞中参与炎症反应,在内皮细胞中调控滑膜血管生成,从多个方面促进骨破坏。成纤维细胞生长因子受体1可能是类风湿关节炎骨破坏的一个重要参与因素,为进一步研究类风湿关节炎治疗靶点提供依据。

成纤维细胞生长因子受体1 抑制剂对胶原诱导关节炎模型大鼠骨破坏的影响

背景:课题组前期的研究表明靶向成纤维细胞生长因子受体1(fibroblast growth factor receptor 1,FGFR1)可能是治疗类风湿性关节炎的有效靶点。目的:探讨FGFR1抑制剂(PD173074)对胶原诱导关节炎模型大鼠骨破坏的影响。方法:将25只雌性SD大鼠随机分为5组,正常对照组、模型组、甲氨蝶呤组、PD173074低剂量组、PD173074高剂量组。除正常对照组外,其余各组大鼠建立Ⅱ型胶原诱导关节炎模型。造模成功后正常组及模型组大鼠腹腔注射无菌PBS,甲氨蝶呤组药物注射剂量为1.04 mg/kg,PD173074低剂量组和高剂量组药物注射剂量分别为5,20 mg/kg,1次/周。给药4周后取材,观察大鼠临床症状以及关节肿胀情况,踝关节Micro-CT三维重建及分析,观察踝关节病理变化,检测关节周围血管生成情况及核因子κB受体活化因子配体的表达,检测关节滑膜中p-FGFR1、血管内皮生长因子A、抗酒石酸酸性磷酸酶的表达,观察肝、脾、肾病理变化并计算肝、脾、肾指数。结果与结论:①PD173074能够减轻模型大鼠踝关节临床症状及关节肿胀,延缓骨质丢失,改善骨结构,减轻关节滑膜侵袭以及软骨骨侵蚀,降低关节周围破骨细胞数量,抑制关节滑膜组织中的血管生成,降低核因子κB受体活化因子配体的表达,抑制FGFR1磷酸化蛋白、抗酒石酸酸性磷酸酶和血管内皮生长因子A的蛋白表达。②大鼠肝、脾、肾病理观察表明经过PD173074治疗后无明显的毒副作用。③研究证明了FGFR1抑制剂能够延缓Ⅱ型胶原诱导关节炎模型大鼠关节炎症及骨破坏的进展,并抑制血管的生成。初步验证了PD173074在Ⅱ型胶原诱导关节炎模型中的治疗作用,其可能是通过抑制FGFR1磷酸化发挥作用,为寻找类风湿性关节炎新的治疗靶点提供了方向。

FGFR1基因耳发育功能及突变致聋机制研究进展

成纤维细胞生长因子受体1(Fibroblast growth factor receptor 1,FGFR1)作为一种生长因子受体,具有酪氨酸激酶活性,通过激活多条下游信号通路参与体内多种组织器官生长发育。FGFR1的致病突变或缺失会引起内耳Corti器毛细胞和支持细胞缺失、I型螺旋神经节神经元(SGN)缺失、神经嵴细胞(NCC)迁移咽弓异常、耳部骨软骨发育异常等,导致不同类型耳聋。本文就FGFR1基因及其蛋白结构功能、FGFR1与耳部发育关系、FGFR1相关综合征性耳聋三部分做一综述,以期为临床相关耳聋的早期针对性干预提供理论依据。

Anti-tumor Angiogenesis with a Recombinant Ag43/FGFR1 Chimeric Protein As a Model Antigen

In order to investigate the anti-tumor angiogenesis activity with a recombinant Ag43/FGFR1 chimeric protein(AF)vaccine in a mouse H22 hepatoma model,tumor volume and survival rate of the mice were studied at a 3-day interval.Microvessel density(MVD)was detected by immunohistochemistry.The endothelial deposition of autoantibodies within tumor tissues was examined by immunofluorescent staining,and anti-FGFR1 antibody-producing B cells(APBCs)were tested by enzyme-linked immunospot(ELISPOT)assay.Compared with t...

The Investigation on bFGF Expression and FGFR1 Gene Mutation in the Tumors of Salivary Gland

目的 :探讨bFGF表达及FGFR1基因突变与涎腺肿瘤发生发展的关系。方法 :采用免疫组织化学技术和RT -PCR -SSCP法 ,对 14例多形性腺瘤、9例腺样囊性癌组织和 11例正常涎腺组织中bFGF表达及相应组织内FGFR1胞内段结构基因进行了检测。结果 :bFGF在多形性腺瘤、腺样囊性癌中的表达明显高于正常涎腺组织 ;FGFR1在 14例多形性腺瘤中 4例检出基因突变 ,9例腺样囊性癌组织中 2例检出突变 ,且发现突变基因位于FGFR1胞内段的近膜区及部分激酶I区。结论 :FGFR1细胞内段激酶活性区的突变可能造成bFGF /FGFR1信号传递异常 。

2型糖尿病合并脑梗死患者血清FGF21、RAGE、DKK1表达情况及其意义

目的探讨2型糖尿病(T2DM)合并脑梗死患者血清成纤维细胞生长因子(FGF)21、晚期糖基化终末产物受体(RAGE)及Dickkopf-1蛋白(DKK1)表达情况及其意义。方法前瞻性选取2021年6月至2023年6月于中部战区总医院治疗T2DM合并脑梗死患者300例纳入试验组,选择同期于本院接受治疗的T2DM患者300例纳入T2DM组,选择同期于本院进行体检的健康者300名纳入对照组。检测并比较3组血清FGF21、RAGE、DKK1表达水平;分析血清FGF21、RAGE、DKK1对T2DM合并脑梗死的诊断价值;分析不同预后T2DM合并脑梗死患者临床资料和血清FGF21、RAGE、DKK1表达水平;分析血清FGF21、RAGE、DKK1与T2DM合并脑梗死预后的相关性;采用多因素Logistic回归分析分析血清FGF21、RAGE、DKK1对T2DM合并脑梗死预后的预测价值。结果试验组血清FGF21、RAGE、DKK1表达水平分别为(3.45±0.36)ng/L、(789.74±80.57)μg/mL、(98.76±9.92)ng/mL,均大于T2DM组[(2.68±0.29)ng/L、(578.06±59.84)μg/mL、(44.76±4.65)ng/mL]及对照组[(1.52±0.17)ng/L、(289.75±30.38)μg/mL、(24.95±2.64)ng/mL],差异均有统计学意义(P<0.05)。经受试者工作特征(ROC)曲线分析,血清FGF21、RAGE及DKK1联合诊断T2DM合并脑梗死的临床价值高于血清FGF21、RAGE及DKK1单一诊断的临床价值。预后不良患者和预后良好患者的性别构成比、年龄、体重指数、随机血糖比较,差异均无统计学意义(P>0.05);预后不良患者的糖化血红蛋白(HbA1c)、FGF21、RAGE、DKK1分别为(8.42±0.86)%、(3.89±0.40)ng/L、(865.64±89.43)μg/mL、(125.64±14.26)ng/mL,均大于预后良好患者[(7.04±0.73)%、(3.11±0.33)ng/L、(735.08±75.07)μg/mL、(83.64±8.61)ng/mL],差异均有统计学意义(P<0.05)。经Spearman相关分析,血清FGF21、RAGE、DKK1与T2DM合并脑梗死预后均呈负相关(r=-0.624、-0.553、-0.726,P<0.05)。经Logistic回归分析,结果显示HbA1c、FGF21、RAGE、DKK1均为影响T2DM合并脑梗死预后的独立危险因素(P<0.05)。结论血清FGF21、RAGE、DKK1联合诊断T2DM合并脑梗死具有较高的诊断及预后价值,可将其应用于T2DM合并脑梗死患者的临床诊断及预后评价。